• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Alkermes plc (Amendment)

    8/24/23 5:18:57 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    SC 13D/A 1 brhc20057973_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 16)*

    Alkermes Public Limited Company
    (Name of Issuer)
     
    Ordinary shares, $0.01 par value
    (Title of Class of Securities)
     
    G01767105
    (CUSIP Number)
     
    Mark DiPaolo
    Senior Partner, General Counsel
    Sarissa Capital Management LP
    660 Steamboat Road
    Greenwich, CT 06830
    203-302-2330
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    August 23, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
     
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G01767105
    Page 2 of 5 Pages
    SCHEDULE 13D
    1
    NAMES OF REPORTING PERSONS
     
     
    Sarissa Capital Management LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    8,323,400
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    8,323,400
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,323,400
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.997%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No. G01767105
    Page 3 of 5 Pages
    SCHEDULE 13D
    1
    NAMES OF REPORTING PERSONS
     
     
    Alexander J. Denner, Ph.D.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    8,323,400
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    8,323,400
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    8,323,400
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.997%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     

    CUSIP No. G01767105
    Page 4 of 5 Pages
    SCHEDULE 13D
    This Amendment No. 16 to Schedule 13D (“Amendment No. 16”) relates to ordinary shares, par value $0.01 per share (“Common Stock” and, such shares, the “Shares”), issued by Alkermes Public Limited Company, a company incorporated under the laws of Ireland (the “Issuer”), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on May 10, 2021 (the “Initial Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on May 27, 2021, Amendment No. 2 to Schedule 13D filed on September 10, 2021, Amendment No. 3 to Schedule 13D filed on November 19, 2021, Amendment No. 4 to Schedule 13D filed on January 10, 2022, Amendment No. 5 to Schedule 13D filed on July 6, 2022, Amendment No. 6 to Schedule 13D filed on October 7, 2022, Amendment No. 7 to Schedule 13D filed on February 6, 2023, Amendment No. 8 to Schedule 13D filed on June 5, 2023, Amendment No. 9 to Schedule 13D filed on June 12, 2023, Amendment No. 10 to Schedule 13D filed on June 14, 2023, Amendment No. 11 to Schedule 13D filed on June 16, 2023, Amendment No. 12 to Schedule 13D filed on June 21, 2023, Amendment No. 13 to Schedule 13D filed on June 23, 2023, Amendment No. 14 to Schedule 13D filed on June 27, 2023 and Amendment No. 15 to Schedule 13D filed on June 28, 2023 (the Initial Schedule 13D, as so amended, the “Schedule 13D”), on behalf of the Reporting Persons, to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    This Amendment No. 16 constitutes an “exit filing” for the Reporting Persons.
     
    Item 5.
    Interest in Securities of the Issuer.
     
    Items 5 (a) and (c) of the Schedule 13D are hereby amended and restated as follows:
     
    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 8,323,400 Shares representing approximately 4.997% of the outstanding Shares, based upon the 166,558,735 Shares outstanding as of July 21, 2023, as set forth in the Form 10-Q of the Issuer filed with the U.S. Securities and Exchange Commission on July 26, 2023.

    (c) Other than as set forth in Schedule I to this Schedule 13D or elsewhere in this Schedule 13D, the Reporting Persons have not engaged in any transactions in the Common Stock during the past sixty days.

    (e) As a result of the transactions set forth in Schedule I to this Amendment No. 16, the Reporting Persons ceased to be the beneficial owners of more than 5% of the Shares.


    CUSIP No. G01767105
    Page 5 of 5 Pages
    SCHEDULE 13D
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: August 24, 2023  
         
    SARISSA CAPITAL MANAGEMENT LP
         
    By:
    /s/ Mark DiPaolo
     
     
    Name: Mark DiPaolo
     
    Title: Senior Partner, General Counsel
         
    /s/Alexander J. Denner
     
    Alexander J. Denner
     


    Schedule I

    Transactions of the Reporting Persons Effected During the Past 60 Days

    The following transactions in the Shares were effected during the past 60 days by the Sarissa Funds in the open market:

    Date of Transaction
    Amount of Security Bought / (Sold)
    Price Per Share
    7/27/2023
    (675,000)
    30.27
    7/28/2023
    (11,600)
    30.20
    7/31/2023
    (500,000)
    29.13
    8/1/2023
    (100,000)
    29.09
    8/2/2023
    (282,000)
    28.15
    8/21/2023
    (90,000)
    29.60
    8/23/2023
    (343,000)
    28.12
    8/23/2023
    (3,220,000)
    28.75
    8/23/2023
    (10,000)
    28.83
    8/24/2023
    (405,000)
    27.59
    8/24/2023
    (50,000)
    27.52
    8/24/2023
    (30,000)
    27.64



    Get the next $ALKS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

      6/17/25 7:46:56 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Alkermes Plc with a new price target

      Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

      5/28/25 8:55:31 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

      RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00

      3/13/25 7:24:22 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    SEC Filings

    See more
    • Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alkermes plc. (0001520262) (Filer)

      5/21/25 4:15:15 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Alkermes plc

      SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

      5/13/25 10:23:10 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Alkermes plc

      DEFA14A - Alkermes plc. (0001520262) (Filer)

      5/12/25 5:03:55 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:39:56 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/10/25 4:37:23 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wright Christopher I covered exercise/tax liability with 1,924 units of Ordinary Shares and converted options into 8,013 units of Ordinary Shares, increasing direct ownership by 42% to 20,505 units (SEC Form 4)

      4 - Alkermes plc. (0001520262) (Issuer)

      6/2/25 4:34:11 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of c

      6/2/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

      – Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the c

      6/2/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

      – Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study – – New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented – DUBLIN, May 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 developm

      5/29/25 7:24:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

      DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

      3/7/24 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

      —  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.  "Dr. Loew's deep knowledge of the oncology fi

      6/1/23 4:01:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Financials

    Live finance-specific insights

    See more
    • Alkermes plc Reports First Quarter 2025 Financial Results

      —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

      5/1/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Report First Quarter Financial Results on May 1, 2025

      DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc  Alkermes plc is a global biopharmaceutic

      4/17/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

      —    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —    GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — —    ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN, Feb. 12, 2025  /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.

      2/12/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alkermes plc

      SC 13G - Alkermes plc. (0001520262) (Subject)

      11/14/24 1:22:34 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/12/24 1:28:21 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alkermes plc

      SC 13G/A - Alkermes plc. (0001520262) (Subject)

      11/8/24 10:46:38 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care